USPTO serial 87048013
MOLECULAR HEALTH GUIDE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 3, 2018
- Examiner
- HISER, CHARLES
- Law office
- Historical data usage
What this means
Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary. Calendar the 10-year Section 8 and 9 combined renewal.
Need help with MOLECULAR HEALTH GUIDE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Peter T. Wakiyama
Peter T. Wakiyama Troutman Pepper Hamilton Sanders LLP3000 Two Logan SquareEighteenth and Arch StreetsPHILADELPHIA, PA 19103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable computer databases containing information in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology; downloadable computer databases containing medical and health information on humans; downloadable computer software for accessing, organizing, indexing, ranking, integrating, linking, referencing, synthesizing, interpreting and analyzing information from databases in the fields of medicine, health care, genomics, pharmaceuticals, life sciences and biotechnology and databases containing medical and health information or records about or relating to humans; downloadable mobile applications for mobile devices, for accessing, organizing, synthesizing, indexing, ranking, integrating, linking, referencing, interpreting and analyzing information from databases in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology and databases containing medical and health information or records about or relating to humans; downloadable mobile applications for accessing databases in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals and pharmaceutical safety, life sciences and biotechnology | ACTIVE | Jun 3, 2016 |
| 038 | Providing access to searchable databases containing medical, pharmaceutical, biological, clinical and genomic information and medical and health information and records, molecular test results and patient specific data about or relating to humans for scientific research purposes; providing access to online databases containing medical, pharmaceutical, biological, clinical, molecular, sequencing and genomic information, disease information, biomarker information and medical or health information or records about or relating to humans and patient specific data, molecular test results, and scientific research for medical diagnostic and treatment purposes; providing access to online software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; providing access to non-downloadable computer software and algorithms for medical diagnostic and treatment purposes | ACTIVE | Jun 3, 2016 |
| 042 | Consulting and research services in the fields of health care, medicine, life sciences, biotechnology, pharmaceuticals, bioinformatics, genomics and pharmaceuticals and pharmaceutical safety for scientific research purposes; consulting and research services in the nature of retrieval, integration, correlation, analysis and interpretation of genomic, sequencing, and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, medical health information patient specific data, molecular test results, data from clinical studies, and scientific research for purposes of scientific, medical and pharmaceutical research; designing and developing searchable databases containing medical, pharmaceutical, biological, clinical and genomic information and medical and health information and records, molecular test results and patient specific data about or relating to humans for scientific research purposes; providing temporary use to non-downloadable computer software and algorithms for managing large amounts of genetic data, accessing genetic information in large databases in use by physicians, clinicians and other healthcare professionals, laboratory personnel, consultants, scientists and other researchers for purposes of scientific, medical and pharmaceutical research; providing temporary use to non-downloadable software and algorithms for retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data and information on diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, patient specific data, molecular test results, data from clinical studies, and scientific research for purposes of scientific, medical and pharmaceutical research; providing temporary use to non-downloadable applications for mobile devices, namely, smart phones and tablets, and web applications accessible through the internet providing information in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals, life sciences and biotechnology for scientific research purposes; data collection services for scientific research purposes in the fields of genomics, health care, pharmaceuticals, life sciences, bioinformatics, biotechnology and medicine; services for mobile devices, namely, smart phones and tablets, being software design; non-downloadable web applications for accessing databases accessible through the internet in the fields of medicine, health care, genomics, bioinformatics, pharmaceuticals and pharmaceutical safety, life sciences and biotechnology; consulting in the fields of biotechnology, bioinformatics, life sciences; providing temporary use of non-downloadable computer software and algorithms for managing large amounts of genetic data, accessing genetic information in large databases for medical diagnostic and treatment purposes; medical research services, namely, the retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; consulting services in the fields of biotechnology, bioinformatics, and life sciences; Medical research services, namely, the retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes | ACTIVE | Jun 3, 2016 |
| 044 | Medical consulting services, namely, the retrieval, integration, correlation, analysis and interpretation of genomic, sequencing and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data, and patient specific data, molecular test results, data from clinical studies, and scientific research for medical diagnostic and treatment purposes; consulting services in the fields of health, medical care, pharmaceuticals and medicine; providing medical information in the fields of health, healthcare, life sciences, biotechnology, pharmaceuticals and pharmaceutical safety, bioinformatics, and genetic testing for medical purposes; medical consulting services with respect to the treatment and diagnosis of individuals; providing medical information on drug safety and drug compatibility in relation to therapy and the treatment of individuals; medical consulting services in the fields of diagnostics and patient treatment and treatment protocols | ACTIVE | Jun 3, 2016 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Molecular Health GmbH
- Other trademarks owned by Molecular Health GmbH
- Other trademarks in Class 009
- Other trademarks in Class 038
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MOLECULAR HEALTH GUIDE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 8, 2025 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Apr 8, 2025 | 8.OK | REGISTERED - SEC. 8 (6-YR) ACCEPTED | The USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline. |
| Apr 7, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Sep 13, 2024 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Jul 3, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jul 3, 2018 | R.SR | REGISTERED-SUPPLEMENTAL REGISTER | Your mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application. |
| May 31, 2018 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 24, 2018 | CNTA | APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER | — |
| May 16, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 16, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 11, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 11, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 14, 2017 | AAUA | NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED | — |
| Nov 11, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 11, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 11, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 11, 2017 | IUAA | USE AMENDMENT ACCEPTED | — |
| Oct 23, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 23, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 10, 2017 | ALIE | ASSIGNED TO LIE | — |
| Sep 28, 2017 | AUPC | AMENDMENT TO USE PROCESSING COMPLETE | — |
| Sep 28, 2017 | IUAF | USE AMENDMENT FILED | — |
| Sep 27, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 27, 2017 | EAAU | TEAS AMENDMENT OF USE RECEIVED | — |
| Mar 27, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 27, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 27, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 16, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 15, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 15, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 15, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 15, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 15, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 8, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 1, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 27, 2016 | NWAP | NEW APPLICATION ENTERED | — |